Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Receives Consensus Rating of “Hold” from Analysts

Shares of Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) have received a consensus rating of “Hold” from the eight research firms that are currently covering the stock, Marketbeat Ratings reports. Six investment analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $32.67.

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group reiterated a “neutral” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th. SVB Leerink cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Leerink Partnrs cut Amylyx Pharmaceuticals from an “outperform” rating to a “market perform” rating in a research note on Monday, March 11th. Mizuho cut Amylyx Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Monday, March 18th. Finally, Evercore ISI restated an “in-line” rating on shares of Amylyx Pharmaceuticals in a research note on Friday, March 8th.

Insider Buying and Selling at Amylyx Pharmaceuticals

In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 2,838 shares of Amylyx Pharmaceuticals stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $18.76, for a total transaction of $53,240.88. Following the completion of the transaction, the insider now owns 46,245 shares of the company’s stock, valued at approximately $867,556.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Amylyx Pharmaceuticals news, insider Gina Mazzariello sold 2,838 shares of Amylyx Pharmaceuticals stock in a transaction dated Friday, February 23rd. The stock was sold at an average price of $18.76, for a total transaction of $53,240.88. Following the completion of the transaction, the insider now owns 46,245 shares of the company’s stock, valued at approximately $867,556.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO James M. Frates sold 1,792 shares of the business’s stock in a transaction dated Tuesday, March 5th. The stock was sold at an average price of $18.73, for a total value of $33,564.16. Following the transaction, the chief financial officer now directly owns 134,784 shares of the company’s stock, valued at approximately $2,524,504.32. The disclosure for this sale can be found here. Insiders sold 10,305 shares of company stock valued at $193,098 in the last quarter. 11.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. China Universal Asset Management Co. Ltd. grew its position in Amylyx Pharmaceuticals by 96.6% during the third quarter. China Universal Asset Management Co. Ltd. now owns 1,730 shares of the company’s stock valued at $32,000 after acquiring an additional 850 shares during the last quarter. Royal Bank of Canada grew its position in Amylyx Pharmaceuticals by 36.2% during the third quarter. Royal Bank of Canada now owns 1,373 shares of the company’s stock valued at $38,000 after acquiring an additional 365 shares during the last quarter. Allspring Global Investments Holdings LLC grew its position in Amylyx Pharmaceuticals by 52,575.9% during the first quarter. Allspring Global Investments Holdings LLC now owns 15,276 shares of the company’s stock valued at $43,000 after acquiring an additional 15,247 shares during the last quarter. Wells Fargo & Company MN grew its position in Amylyx Pharmaceuticals by 79.6% during the fourth quarter. Wells Fargo & Company MN now owns 1,719 shares of the company’s stock valued at $64,000 after acquiring an additional 762 shares during the last quarter. Finally, Point72 Hong Kong Ltd bought a new position in Amylyx Pharmaceuticals during the fourth quarter valued at approximately $75,000. 95.84% of the stock is currently owned by institutional investors.

Amylyx Pharmaceuticals Price Performance

NASDAQ AMLX opened at $1.87 on Monday. The stock has a market capitalization of $126.75 million, a price-to-earnings ratio of 2.67 and a beta of -0.93. Amylyx Pharmaceuticals has a one year low of $1.85 and a one year high of $31.28. The business’s fifty day moving average is $8.27 and its 200-day moving average is $12.90.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last released its earnings results on Thursday, February 22nd. The company reported $0.23 EPS for the quarter, topping analysts’ consensus estimates of $0.20 by $0.03. The company had revenue of $108.45 million for the quarter, compared to analysts’ expectations of $106.40 million. Amylyx Pharmaceuticals had a return on equity of 12.39% and a net margin of 12.94%. During the same period in the previous year, the business posted ($0.65) EPS. Research analysts expect that Amylyx Pharmaceuticals will post -1.01 EPS for the current fiscal year.

About Amylyx Pharmaceuticals

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.